Clinical Trials Logo

Filter by:
NCT ID: NCT04742543 Recruiting - Dysplasia, Cervix Clinical Trials

Virtual Reality During Conization of Cervix Uterus Under Local Anesthesia

Start date: May 19, 2022
Phase: N/A
Study type: Interventional

To evaluate the effectiveness of virtual reality glasses as a distraction technique in the management of acute pain and anxiety during conization of cervix uterus under local anesthesia

NCT ID: NCT04741113 Completed - Obese, Stigma Clinical Trials

The Effect of an Education Module to Reduce Weight Bias Among Healthcare Professionals in a Private Hospital Setting

Start date: January 6, 2021
Phase: N/A
Study type: Interventional

Although scientific bodies have recognized obesity as a disease, obese people are often stigmatized, facing discrimination, and accusations that they are responsible to their condition due to their lack of willpower by healthcare professionals. However, experimental research to reduce weight bias among healthcare professionals is lacking, and published studies to date are methodologically flawed, including lack of randomization, lack of control group and small sample size. The study is designed to evaluate the effect of a comprehensive online education module on knowledge about obesity and weight bias in a convenience sample in a private hospital setting. This is an interventional study conducted among all Assuta Medical Centers healthcare employees including physicians, bariatric surgeons, nurses, dietitians, social workers, physiotherapists, pharmacists, imaging department technicians, laboratory workers, patient services assistants and medical secretariats. Participants who will confirm their consent to participate in the study, will be randomized into two arms: intervention vs. control (with no intervention). The study intervention will include an online 15-minute educational module which will be based on relevant literature and expert opinion and will include four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz. At baseline, one week and one-month post intervention, both groups will respond to an anonymous on-line survey on knowledge about obesity and weight stigma. Moreover, data on demographic parameters of study participants will be collected.

NCT ID: NCT04740931 Completed - Macular Edema Clinical Trials

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

COMINO
Start date: March 2, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).

NCT ID: NCT04740905 Completed - Macular Edema Clinical Trials

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

BALATON
Start date: March 2, 2021
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in participants with macular edema due to branch retinal vein occlusion (BRVO).

NCT ID: NCT04740333 Completed - Sepsis Clinical Trials

Prognostic Impact of Admission Glucose Level in Septic Patients Admitted to the Intensive Care Unit

Start date: December 1, 2023
Phase:
Study type: Observational

Background: Sepsis is one of the most common reasons for admission to intensive care units (ICU) worldwide. About 30% of all patients admitted to intensive care suffer from sepsis (1). Sepsis causes an extreme physiological stress response, with significant changes in metabolism and disruption in glucose regulation. Disorder of glucose regulation can lead to hyperglycemia, hypoglycemia and glucose variability (2). All of these conditions are associated with increased mortality (3). In critically-ill patients, the glucose threshold from which damage may be caused remains controversial. Hyperglycemia often occurs in critically-ill patients suffering from sepsis, even in those who were not diabetic before, for several reasons. Sepsis causes massive activation of anti-inflammatory mediators which enhances the activity of counter-regulatory hormones, including cortisol, glucagon and catecholamines. Those hormones increase both hepatic gluconeogenesis and peripheral resistance to insulin (4). Some of the detrimental effects of hyperglycemia in septic patients are mediated via hyperglycemia-induced blood hypercoagulable state, decrease of vascular endothelial responsiveness and disrupted process of phagocytosis and chemotaxis of white blood cells, especially neutrophils (5). It is widely accepted that disordered blood glucose regulation increases mortality and morbidity, as well as hospital admission times and associated financial expenses (2,6). Blood glucose level at ICU admission was found to be a poor prognostic factor at various studies on different ICU patient populations (7-9). For example, in ICU patients admitted due to acute myocardial infarction, cardiogenic shock and need for urgent cardiac catheterization, high blood glucose levels at admission, even in non-diabetic patients, were associated with both increased in- hospital and long-term mortality (7). Among patients admitted due to acute heart failure, high admission glucose levels (above 200 mg / dL), in both diabetic and non-diabetic patients, were associated with higher mortality from cardio-vascular etiologies within one year of admission (8). Among non-diabetic patients admitted to the hospital due to acute myocardial infarction, admission glucose levels above 180 mg / dL were associated with a significant increase in all-causes in-hospital mortality (9). However, there is currently insufficient information regarding the prognostic impact of high admission glucose levels of non-diabetic septic patients admitted to the ICU (10).

NCT ID: NCT04739059 Active, not recruiting - Clinical trials for Hereditary Angioedema

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Start date: March 29, 2021
Phase: Phase 3
Study type: Interventional

This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC)

NCT ID: NCT04737395 Recruiting - Stroke Clinical Trials

Intensive Upper Extremity Training Program During the Early Subacute Phase After Stroke: A Feasibility Study

Start date: November 22, 2020
Phase: N/A
Study type: Interventional

The study assesses the feasibility of a 4-week upper extremity training program emphasizing quality of movement practiced at high intensity and dosage applied during the early subacute phase after stroke.

NCT ID: NCT04734119 Completed - Anesthesia Clinical Trials

Patient Satisfaction With Perioperative Anesthetic Care

Start date: December 1, 2018
Phase:
Study type: Observational

The doctor-patient relationship, medical competence and patient expectations influence patient satisfaction with anesthesia. Preoperatively all patients are routinely assessed by an anesthesiologist. However, in many centers, the anesthesiologist who performs the preoperative evaluation will not necessarily be the anesthesiologist who provides the intraoperative service. This study evaluated the effect of this practice on patient satisfaction, level of confidence and anxiety among adult patients undergoing elective surgery.

NCT ID: NCT04733833 Completed - Severe COVID-19 Clinical Trials

A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19

Start date: January 26, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2 study is to test safety, efficacy, and tolerability of an oral preparation of VB-201 in patients with severe COVID-19

NCT ID: NCT04732949 Completed - COVID-19 Clinical Trials

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

SPRINTER
Start date: January 12, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this Phase III study is to confirm that SNG001 can accelerate the recovery of hospitalised patients receiving oxygen with confirmed Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Safety and other efficacy endpoints will also be assessed.